Literature DB >> 23179964

Diagnostic delay is associated with psychosocial impairment in acromegaly.

Sonja Siegel1, Christine Streetz-van der Werf, Jennifer S Schott, Kay Nolte, Wolfram Karges, Ilonka Kreitschmann-Andermahr.   

Abstract

The aim of this study was to systematically assess health care utilisation, diagnostic delay and psychosocial impairment in patients with acromegaly in rural versus urban health care environments. 41 patients with acromegaly were questioned to time lapse of symptom onset, first seeking medical advice and time of acromegaly diagnosis. Quality of life (QoL), and psychosocial impairment (depression, daytime sleepiness, sleep disturbances, disturbances of body image) were measured by self-assessment questionnaires. Patients were grouped into living in rural health care environments (RHCE, n = 22 patients) or urban health care environments (UHCE, n = 19 patients) using data on population density from the German Federal Statistical Office. RHCE patients waited significantly longer (2.5 vs. 0.89 years; p = .025) after symptom onset before seeking medical advice, but diagnosis of acromegaly was established at least as quickly as in UHCE (1.45 vs. 2.74 years; n.s.). There was a consistent trend toward more psychosocial impairment in UHCE which reached significance for sleep disturbances (p = .004). For all patients significant correlations between time delay of diagnostic process (defined as first visit to the doctor because of acromegaly-related symptoms and establishment of acromegaly diagnosis) and psychological QoL, depression, daytime sleepiness, sleep disorders and body image emerged. Patients with acromegaly in UHCE experienced more psychosocial impairment than patients in RHCE. The correlation of significantly increased psychosocial impairment and delay of diagnosis by the physician may reflect long-lasting embitterment in patients with acromegaly and should be considered during psychosocial counselling.

Entities:  

Mesh:

Year:  2013        PMID: 23179964     DOI: 10.1007/s11102-012-0447-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  23 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

2.  [Predictors for ambulatory medical care utilization in Germany].

Authors:  N Thode; E Bergmann; P Kamtsiuris; B-M Kurth
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2005-03       Impact factor: 1.513

Review 3.  An overview of the epidemiology and genetics of acromegaly.

Authors:  A F Daly; P Petrossians; A Beckers
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

4.  [Clinical picture, diagnosis and therapy of acromegaly patients in Eastern and Western Germany].

Authors:  A Teubner; M Breidert; T Baehring; J Hensen; S R Bornstein
Journal:  Z Arztl Fortbild Qualitatssich       Date:  1997-12

Review 5.  Quality of life in growth hormone deficiency and acromegaly.

Authors:  Susan M Webb; Xavier Badia
Journal:  Endocrinol Metab Clin North Am       Date:  2007-03       Impact factor: 4.741

Review 6.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

7.  Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.

Authors:  Maria P Matta; Elisabeth Couture; Laurent Cazals; Delphine Vezzosi; Antoine Bennet; Philippe Caron
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

8.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

Review 9.  Posttraumatic embitterment disorder.

Authors:  Michael Linden
Journal:  Psychother Psychosom       Date:  2003 Jul-Aug       Impact factor: 17.659

10.  Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.

Authors:  Agatha A van der Klaauw; Nienke R Biermasz; Hendrieke C Hoftijzer; Alberto M Pereira; Johannes A Romijn
Journal:  Clin Endocrinol (Oxf)       Date:  2008-07-01       Impact factor: 3.478

View more
  16 in total

1.  Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL.

Authors:  Cornelie D Andela; Nicolasine D Niemeijer; Margreet Scharloo; Jitske Tiemensma; Shaaji Kanagasabapathy; Alberto M Pereira; Noëlle G A Kamminga; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 2.  Diabetes in Patients With Acromegaly.

Authors:  A M Hannon; C J Thompson; M Sherlock
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

Review 3.  Update on quality of life in patients with acromegaly.

Authors:  Iris Crespo; Elena Valassi; Susan M Webb
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.

Authors:  Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

5.  Diagnosis and management of acromegaly: the patient's perspective.

Authors:  Ilonka Kreitschmann-Andermahr; Sonja Siegel; Bernadette Kleist; Johannes Kohlmann; Daniel Starz; Rolf Buslei; Maria Koltowska-Häggström; Christian J Strasburger; Michael Buchfelder
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

6.  Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?

Authors:  Panagiotis Anagnostis; Zoe A Efstathiadou; Maria Charizopoulou; Despina Selalmatzidou; Eleni Karathanasi; Maria Poulasouchidou; Marina Kita
Journal:  Endocrine       Date:  2014-02-08       Impact factor: 3.633

Review 7.  Cognitive-behavioral therapy improves the quality of life of patients with acromegaly.

Authors:  Lia Silvia Kunzler; Luciana Ansaneli Naves; Luiz Augusto Casulari
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

8.  Patient perspectives on the impact of acromegaly: results from individual and group interviews.

Authors:  Michelle H Gurel; Paul R Bruening; Christine Rhodes; Kathleen G Lomax
Journal:  Patient Prefer Adherence       Date:  2014-01-09       Impact factor: 2.711

9.  Patient-focussed outcomes in acromegaly.

Authors:  Mirtha Guitelman; Alin Abreu; Ana Laura Espinosa-de-los-Monteros; Moisés Mercado
Journal:  Pituitary       Date:  2014-01       Impact factor: 4.107

Review 10.  Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.

Authors:  Alin Abreu; Alejandro Pinzón Tovar; Rafael Castellanos; Alex Valenzuela; Claudia Milena Gómez Giraldo; Alejandro Castellanos Pinedo; Doly Pantoja Guerrero; Carlos Alfonso Builes Barrera; Humberto Ignacio Franco; Antônio Ribeiro-Oliveira; Lucio Vilar; Raquel S Jallad; Felipe Gaia Duarte; Mônica Gadelha; Cesar Luiz Boguszewski; Julio Abucham; Luciana A Naves; Nina Rosa C Musolino; Maria Estela Justamante de Faria; Ciliana Rossato; Marcello D Bronstein
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.